Current understanding of the role of insulin-like and vascular endothelial growth factors in development, prognosis and targeted therapy in patients with ovarian cancer
- Authors: Knyazev RI1, Poddubnaya IV1, Barinov VV2, Bokin II1
-
Affiliations:
- Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian
- N.N.Blokhin Russian Cancer Research Center
- Issue: Vol 17, No 3 (2015)
- Pages: 105-108
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27045
- ID: 27045
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
R I Knyazev
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian
Email: sluwba@mail.ru
аспирант каф. онкологии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
I V Poddubnaya
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russianд-р мед. наук, проф., чл.-кор. РАН, зав. каф. онкологии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
V V Barinov
N.N.Blokhin Russian Cancer Research Centerд-р мед. наук, проф., вед. науч. сотр. отд-ния гинекологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
I I Bokin
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russianканд. мед. наук, ассистент каф. онкологии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
References
- Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. М.: РОНЦ им. Н.Н.Блохина, 2014; с. 51-66.
- Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). М.: МНИОИ им. П.А.Герцена, 2015.
- Клиническая онкогинекология: Руководство для врачей. Под ред. В.П.Козаченко. М.: Медицина, 2005.
- Хохлова С.В. Роль бевацизумаба в лечении рака яичников. Онкогинекология. 2012; 3: 33-45.
- Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). М.: МНИОИ им. П.А.Герцена, 2013.
- An Y et al. Local expression of insulin - like growth factor-I, insulin - like growth factor-I receptor, and estrogen receptor alpha in ovarian cancer. Oncol Res Treat 2009; 32 (11): 638-44.
- Bao B et al. Hypoxia - induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PloS one 2012; 7 (12): e50165.
- Baxter R.C. IGF binding proteins in cancer: mechanistic and clinical insights. Nature Rev Cancer 2014; 14 (5): 329-41.
- Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocrine - related cancer 2011; 18 (4): R125-R147.
- Beltran P.J et al. Ganitumab (AMG 479) Inhibits IGF-II-Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy. Clin Cancer Res 2014; 20 (11): 2947-58.
- Brokaw J et al. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007; 25 (5): 346-54.
- Bruchim I et al. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer 2010; 20; 7: 1148-53.
- Bruchim I, Sarfstein R, Werner H. The IGF hormonal network in endometrial cancer: functions, regulation, and targeting approaches. Frontiers in Endocrinol 2014; 5.
- Brustmann H. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase IIa and prognosis. Gynecol Oncol 2004; 95 (1): 16-22.
- Burger R.A et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365 (26): 2473-83.
- Cao Y et al. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer 2015; 136 (10): 2418-26.
- Chakraborty A.K, Welsh A, Di Giovanna M.P. Co - targeting the insulin - like growth factor I receptor enhances growth - inhibitory and pro - apoptotic effects of anti - estrogens in human breast cancer cell lines. Breast Cancer Res Treat 2010; 120 (20): 327-35.
- Chen H et al. Correlation of the expressions of VEGF-C and VEGFR-3 to the pathological grade of prostate cancer. Nan fang yi ke da xue xue bao. J South Med Univ 2011; 31 (1): 155-9.
- Cheng D, Liang B, Li Y. Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PloS One 2013; 8 (2): e55309.
- Crociani O et al. hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implications. Clin Cancer Res 2014; 20 (6): 1502-12.
- Evans T et al. Phase I dose - escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin - like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. ASCO Meeting Abstracts 2010; 28: 2531.
- Flannery C.A et al. SAT-0017: Differential Expression of IR-a, IR-B and IGF-1R in Endometrium Reflects Physiology during the Menstrual Cycle and Demonstrates a Distinct Expression Signature in Endometrial Adenocarcinoma. 2014.
- Gadducci A et al. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res 2002; 23 (3C): 3001-8.
- Gao J et al. Targeting the insulin - like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 2012; 72 (10): 3-12.
- Garcı́a-Echeverrı́a C et al. In vivo antitumor activity of NVP-AEW541 - a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5 (3): 231-9.
- Gotlieb W.H et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double - blind, placebo - controlled study. Lancet Oncol 2012; 13 (20): 154-62.
- Guleria S, Sharma J, Kaushik S. Laron syndrome. J Postgraduate Med 2014; 60 (3): 322.
- Gungor A et al. FRI-319: Hypoinsulinemic Hypoglycemia Secondary to Solitary Fibrous Tumor of the Pleura: Doege-Potter Syndrome; A Case Report 2015.
- Haluska P et al. Phase I dose - escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res 2014; 20 (18): 4747-57.
- Harb W.A et al. Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin - like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors. J Clin Oncol 2013; 31 (15).
- He L, He J, Zhao X. Expression of VEGF-D in epithelial ovarian cancer and its relationship to lymphatic metastasis. Asia-Pacific J Clin Oncol 2013.
- Herr D et al. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol 2012; 127 (1): 210-6.
- Hormones T.E, Group B.C.C. Insulin - like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010; 11 (6): 530-42.
- Huang Y.F et al. Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocrine - related cancer 2014; 21 (2): 217-29.
- Ioannou N et al. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC cancer 2013; 13 (1): 41.
- Kauppinen-Mäkelin R et al. Increased cancer incidence in acromegaly - a nationwide survey. Clin Endocrinol 2010; 72 (2): 278-9.
- Khromova N et al. Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene 2011; 31 (11): 1389-97.
- Liang B et al. Elevated VEGF concentrations in ascites and serum predict adverse prognosis in ovarian cancer. Scan J Clin Lab Investiga 2013; 73 (4): 309-14.
- Lu L et al. The relationship of insulin - like growth factor-II, insulin - like growth factor binding protein-3, and estrogen receptor - alpha expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 2006; 12 (4): 1208-14.
- Ludovini V et al. Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease - free survival of surgically resected non - small - cell - lung cancer patients. Cancer Chemother Pharmacol 2013; 71 (3): 671-80.
- Mikami K et al. Prostate cancer risk in relation to insulin - like growth factor (IGF)-I and IGF-binding protein-3: A nested case - control study in large scale cohort study in Japan. Asian Pacific J Cancer Prevent: APJCP 2009; 10: 57-61.
- Molife L.R et al. The insulin - like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose - escalation, open - label study. Br J Cancer 2010; 103 (3): 332-9.
- Moroney J.W, Sood A.K, Coleman R.L. Aflibercept in epithelial ovarian carcinoma. Future Oncology 2009; 5 (5): 591-600.
- Nakazawa Y et al. A multi - targeting strategy using lenvatinib and golvatinib: Maximizing its anti - angiogenesis activity in preclinical cancer model. Cancer Sci 2014.
- National cancer institute. Surveillance, epidemiology, and end results program. http://seer.cancer.gov/statfacts/html/ovary.html
- Park J.H et al. Matrix metalloproteinase 9 promotes breast cancer through regulation of insulin - like growth factor - binding proteins. Cancer Res 2012; 72 (8 Suppl.): 2465.
- Pengchong H, Tao H. Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Eur J Gynaecol Oncol 2010; 32 (6): 660-4.
- Reinhardt H.C, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends in Genetics 2012; 28 (3): 128-36.
- Rinaldi S et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta - analysis of prospective studies. Int J Cancer 2010; 126 (7): 1702-15.
- Salvesen H.B, Haldorsen I.S, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 2012; 13 (8): e353-e361.
- Samani A.A et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Rev 2007; 28 (1): 20-47.
- Sayer R.A et al. High insulin - like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol 2005; 96 (2): 355-61.
- Soufla G, Sifakis S, Spandidos D.A. FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium. Cancer letters 2008; 259 (2): 146-55.
- Spentzos D et al. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocrine - related Cancer 2007; 14 (3): 781-90.
- Steuerman R, Shevah O, Laron Z. Congenital IGF1 deficiency tends to confer protection against post - natal development of malignancies. Eur J Endocrinol 2011; 164 (4): 485-9.
- Tas F et al. Clinical significance of serum insulin - like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumor Biol 2014; 35 (4): 3125-32.
- Wagner A.D et al. Vascular - endothelial - growth - factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev 2012; 7.
- Wang F et al. Vascular endothelial growth factor - regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 2006; 118 (4): 879-88.
- Wang H et al. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. Clinica Chimica Acta 2014; 436: 243-48.
- Werner H, Bruchim I. IGF-1 and BRCA1 signalling pathways in familial cancer. Lancet Oncol 2012; 13 (12): e537-e544.
- Wong C, Wellman T.L, Lounsbury K.M. VEGF and HIF-1a expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003; 91 (3): 513-7.